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diseasesIn Allergology International (AI) Vol. 65 Issue 2, we offer a set of
review articles entitled “Genetic or epigenetic regulations in im-
mune responses and allergic diseases” as well as original articles
and letters to the editor. We believe that this review series will pro-
vide you with new understandings of immune responses and
allergic diseases controlled in a transcriptional or an epigenetic
manner.
Both basophils and mast cells are important players at immune
responses and allergic diseases.1,2 In spite of some similarities, such
as expression of high-afﬁnity IgE receptor on cell surfaces, they
have different characteristicsddistribution in bodies and life
spandso their functions are non-redundant. Basophils and mast
cells develop from their common progenitors via their own progen-
itors. Several critical transcriptional factors are involved in their
development, and these transcriptional factors organize hierarchi-
cal cascades. Prof. Tamura's group introduces the developmental
pathways of basophils and mast cells as well as the transcriptional
factors regulating their development.3 They show the importance
of the IRF8-GATA2 pathway in generating the basophil/mast cell-
common progenitors called pre-basophil and mast cell progenitors
(pre-BMPs), whereas the STAT5-GATA2 pathways, followed by C/
EBPa or MITF, determine the fate of pre-BMPs into basophils or
mast cells, respectively. Moreover, C/EBPa or MITF expressed in
mature basophils or mast cells, respectively, inhibits each other's
expression, stabilizing differentiation. Thus, a sophisticated
network of transcriptional factors orchestrates the development
of basophils and mast cells.
Prof. Vercelli presents the concept of epigenetics as well as the
status of epigenetics studies in allergic diseases.4 Epigenetics is
deﬁned as heritable changes in gene activity that are independent
of alterations in the underlying DNA sequence.5e7 The potential
role of epigenetics in allergic diseases is drawing more attention.
One reason is that since epigenetic mechanisms transduce environ-
mental signals and regulate developmental programs, it is possible
that epigenetic regulation is involved in allergic diseases. Another is
that genome-wide association studies (GWAS) cannot fully account
for phenotypic variance in asthma in spite of the strong genetic
component in asthma. Prof. Vercelli introduces some results of epi-
genetics studies in allergic diseases in this review article; however,
she says that research into asthma and allergy epigenetics is still in
its infancy and that several hurdles must be overcome for the ﬁeld
to bloom.Peer review under responsibility of Japanese Society of Allergology.
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licenses/by-nc-nd/4.0/).Among the contributors to this issue, Yoshida et al. report the
factors associated with the severity of rhinoconjunctivitis using a
nation-wide, web-based survey.8 Allergic rhinitisdcharacterized
by rhinorrhea, sneezing, nasal obstruction, and nasal itchingdthat
is accompanied by ocular symptoms is referred to as allergic rhino-
conjunctivitis.9 The symptoms start mostly before the age of
twenty, becoming evident in 40% of patients by the age of six.10
The authors enrolled 26,725 children from six to twelve years old,
among whom 5175 (19.4%) presented current rhinoconjunctivitis.
Living in areas with a high cedar and cypress pollen count; having
concurrent eczema; and a maternal, but not paternal, history of
asthma and allergic rhinitis were risk factors for severe rhinocon-
junctivitis, whereas living with fur-bearing animals (pets) before
the age of one was a protective factor against it. This study shows
that environmental factors such as pets, pollen, comorbidities,
and a maternal history of allergic diseases could be important in
determining the severity of rhinoconjunctivitis.
Tsuji et al. show the therapeutic efﬁcacy of immunomodulator
FTY720 (ﬁngolimod) on mite extract-treated NC/Nga mice.11
FTY720 is a compound modiﬁed from myriocin (ISP-I) derived
from Isaria sinclairii, a fungus used in traditional Chinese medi-
cine.12,13 FTY720 was discovered by Prof. Fujita in collaboration
with Japanese pharmacological companies. FTY720 has immuno-
suppressive activities different from other immunosuppressive
agents such as tacrolimus hydrate or cyclosporine, and it has
been approved for treatment of multiple sclerosis in many coun-
tries. On the other hand, mite extract-treated NC/Nga mice mani-
fest steroid-resistant atopic dermatitis-like skin inﬂammation. In
these mice, FTY720 improved skin inﬂammation, including
epidermal barrier dysfunction. This study shows promising useful-
ness of FTY720 in treating intractable atopic dermatitis.
It is widely accepted that the prevalence of allergic diseases has
risen worldwide; however, some reports show stable or even
decreasing rates of childhood allergic diseases in Western devel-
oped countries.14,15 Kim et al. examined the prevalence of allergic
diseases in Korea from 2009 to 2014 based on the Korean National
Health Insurance database.16 Because a single mandatory nation-
wide insurance system was established by the government in
1989, Korea has a nationwide disease database that includes virtu-
ally everyone in the country. The prevalence of atopic dermatitis,
allergic rhinitis, and asthma in 2014 was 19.0, 133.1, and 36.3 per
1000 people, respectively. The prevalence of allergic rhinitis contin-
uously increased (by 3.2% per year on average), especially in the age
group under ten, whereas that of atopic dermatitis and asthmavier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Editorial / Allergology International 65 (2016) 121e122122slightly decreased in the past six years (by 2.6% and 5.8% per
year on average). This is the ﬁrst report using a nationwide data-
base to suggest that the prevalence of chronic allergic diseases
might have reached a plateau or have already have begun to decline
in some Asian country.
We offer our appreciation to all the authors for their contribu-
tions to the present issue of Allergology International.
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